Daratumumab monotherapy for treating relapsed and refractory multiple myeloma - NICE TAG TA510

1.1 Daratumumab monotherapy is recommended for use within the Cancer Drugs Fund as an option for treating relapsed and refractory multiple myeloma in adults whose previous therapy included a proteasome inhibitor and an immunomodulator, and whose disease progressed on the last therapy, only if:

• they have daratumumab after 3 previous therapies and

• the conditions in the managed access agreement are followed.

1.2 This recommendation is not intended to affect treatment with daratumumab that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published until they and their NHS clinician consider it appropriate to stop.

https://www.nice.org.uk/guidance/ta510